STOCK TITAN

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) to present at two investor conferences in March 2024, showcasing mRNA cell therapy for autoimmune diseases.
Positive
  • None.
Negative
  • None.

GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March:

  • A presentation at the 2024 Leerink Partners Global Biopharma Conference at 8:40 a.m. ET on Wednesday, March 13, 2024 in Miami, FL
  • A fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference at 11:00 a.m. ET on Tuesday, March 26, 2024

A live webcast of the presentation and fireside chat are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.

About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD. Learn more at www.cartesiantherapeutics.com and follow us on LinkedIn and X, formerly known as Twitter.

Contact Information:
Investor Relations:
Melissa Forst
Argot Partners
cartesian@argotpartners.com

Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com

 


FAQ

When will Cartesian Therapeutics, Inc. (RNAC) participate in the 2024 Leerink Partners Global Biopharma Conference?

Cartesian Therapeutics, Inc. (RNAC) will present at the 2024 Leerink Partners Global Biopharma Conference at 8:40 a.m. ET on Wednesday, March 13, 2024 in Miami, FL.

Where can investors watch the live webcast of Cartesian Therapeutics, Inc. (RNAC) presentation and fireside chat?

Investors can watch the live webcast of Cartesian Therapeutics, Inc. (RNAC) presentation and fireside chat in the Events section of the Company’s website at www.cartesiantherapeutics.com.

What type of therapy is Cartesian Therapeutics, Inc. (RNAC) pioneering for autoimmune diseases?

Cartesian Therapeutics, Inc. (RNAC) is pioneering mRNA cell therapy for autoimmune diseases.

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

RNAC Rankings

RNAC Latest News

RNAC Stock Data

502.92M
1.09M
40.11%
12.34%
5.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WATERTOWN

About RNAC

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat